#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Spinal muscular atrophy Renal cancer metastatic Dementia with Lewy bodies Liposarcoma Hereditary neuropathic amyloidosis Systemic mastocytosis Rheumatoid arthritis Anaplastic large cell lymphoma T- and null-cell types Diffuse large B-cell lymphoma Progressive familial intrahepatic cholestasis Ocular lymphoma Hairy cell leukaemia recurrent Craniopharyngioma Medulloblastoma recurrent Duchenne muscular dystrophy gene carrier More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma Loeys-Dietz syndrome – Treatment Amyotrophic lateral sclerosis – Trials in Disease Mantle cell lymphoma refractory Friedreich’s ataxia – Basic Information Paraneoplastic neurological syndrome – Trials in Disease Kearns-Sayre syndrome – Diagnostics Progressive supranuclear palsy – Life with Disease Systemic mastocytosis – Treatment Cystic fibrosis lung – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cldn6 Car-T(A) Interferon Alfa Ceftriaxone Rizolipase Rbl016.2 Raludotatug Deruxtecan Munc-Cd34 [14C]ZIPALERTINIB Tramadol Hydrochloride Hypothalamic Phospholipids Golimumab DAPIGLUTIDE Caspofungin Lumateperone Disitamab Vedotin Aficamten Suxamethonium Chloride Ep0042 Exagamglogene Autotemcel Aluminium Oxide More therapies…

    Learn about Your Condition

    Colorectal adenoma Systemic candida Haemorrhoids Uveitis Combined immunodeficiency Plasma cell myeloma refractory Implantation complication Diffuse large B-cell lymphoma Deafness bilateral Embolism Pemphigoid Adenosquamous cell lung cancer Underweight Squamous cell carcinoma Mucopolysaccharidosis I More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Tolna Vármegyei Balassa János Kórház

Tolna Vármegyei Balassa János Kórház

Beri Balogh Adam Utca 5-7, Szekszard, 7100, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

    Not recruiting

    3 1
    Investigated Diseases:
    • Heart failure with reduced ejection fraction
    Investigated Drugs:
    • Vericiguat
    Austria Czechia Denmark France Germany Greece +6

  • Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Finland France +9

  • Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Darolutamide
    Belgium Bulgaria Czechia Estonia Finland France +11

  • Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Clopidogrel
    • Milvexian
    • Prasugrel
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Inclisiran
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study Comparing Oral Paclitaxel (DHP107) and IV Paclitaxel for Patients with Recurrent or Metastatic HER2 Negative Breast Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer recurrent
    • Human epidermal growth factor receptor negative
    Investigated Drugs:
    • Paclitaxel
    Hungary

  • Study on Aticaprant for Adults with Major Depressive Disorder and Anhedonia Not Responding to Antidepressants

    Not recruiting

    3 1
    Investigated Diseases:
    • Major depression
    Investigated Drugs:
    • Aticaprant
    Belgium Bulgaria Czechia Finland Hungary Poland +2

  • Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Asundexian
    • Apixaban
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • Study on the Safety and Efficacy of PF-06835375 and Diphenhydramine Hydrochloride for Adults with Moderate to Severe Primary Immune Thrombocytopenia

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Diphenhydramine Hydrochloride
    • Pf-06835375
    Czechia Hungary Poland
Previous Page
1 … 4 5 6

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!